Microorganism susceptible to beta lactam antibiotics are fastly becoming resistant because of production of beta lactamase by microorganisms. This study is aimed at evaluating microbial efficacy of Sulbactomax drug, a novel fixed dose combination of beta lactam antibiotic Ceftriaxone and beta lactamase inhibitor Sulbactam drugs. Efficacy was evaluated on the basis of Minimum Inhibitory Concentration (MIC) and time kill curve analysis in Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Bacillus subtilis and Klebsiella pneumoniae. The MIC for Sulbactomax in E. coli was 0.0625 mg/l whereas Ceftriaxone alone showed MIC of 0.25 mg/l. In case of S. aureus and P. aeruginosa MIC were found to be 1 mg/l for Sulbactomax and 2 mg/l for Ceftriaxone. There was significant reduction of MIC values to 8 mg/l of Sulbactomax from 32mg/l of Ceftriaxone in B. subtilis and 2mg/l of Sulbactomax from 16mg/l of Ceftriaxone. In all organisms under study, time-kill curve analysis demonstrated bacterial maximum killing at 6 hours. Sulbactomax demonstrated better bactericidal activity than Ceftriaxone alone. In conclusion, Sulbactomax was found to have more bacterial inhibiting properties than Ceftriaxone alone in in vitro analysis.
Keywords: Sulbactomax, ceftriaxone, MIC, time kill curve
Rights & PermissionsPrintExport